Lipid profiles of people with human immunodeficiency virus with dyslipidemia after switching from efavirenz to dolutegravir

Long-term weight gain after initiating combination antiretroviral therapy in treatment-naïve Asian people living with human immunodeficiency virus

(2021) Naokatsu Ando et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Do All Integrase Strand Transfer Inhibitors Have the Same Lipid Profile? Review of Randomised Controlled Trials in Naïve and Switch Scenarios in HIV-Infected Patients

(2021) Maria Saumoy et al.   Journal of Clinical Medicine

Lower incidence of HIV-1 blips observed during integrase inhibitor-based combination antiretroviral therapy

(2021) Suzan Dijkstra et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Greater Weight Gain in Treatment Naïve Persons Starting Dolutegravir-Based Antiretroviral Therapy

(2019) Kassem Bourgi et al.   CLINICAL INFECTIOUS DISEASES

Dolutegravir-Based or Low-Dose Efavirenz–Based Regimen for the Treatment of HIV-1

(2019)   NEW ENGLAND JOURNAL OF MEDICINE

Dolutegravir monotherapy and body weight gain in antiretroviral naïve patients

(2019) Sebastiano Rizzardo et al.   AIDS

Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials

(2019) Paul E Sax et al.   CLINICAL INFECTIOUS DISEASES

Weight gain and integrase inhibitors

(2019) Allison Ross Eckard et al.   CURRENT OPINION IN INFECTIOUS DISEASES

Obesity following ART initiation is common and influenced by both traditional and HIV-/ART-specific risk factors

(2018) David R Bakal et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA)

(2018) Lucia Taramasso et al.   BMC INFECTIOUS DISEASES

Brief Report

(2017) Jamison Norwood et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Weight Gain: A Possible Side Effect of All Antiretrovirals

(2017) Lucia Taramasso et al.   Open Forum Infectious Diseases

Rising Obesity Prevalence and Weight Gain Among Adults Starting Antiretroviral Therapy in the United States and Canada

(2016) John R. Koethe et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Improvement of lipid profiles when switching from efavirenz to rilpivirine in HIV-infected patients with dyslipidemia

(2016) Pornpimol Thamrongwonglert et al.   HIV CLINICAL TRIALS

Comparative Changes of Lipid Levels in Treatment-Naive, HIV-1-Infected Adults Treated with Dolutegravir vs. Efavirenz, Raltegravir, and Ritonavir-Boosted Darunavir-Based Regimens Over 48 Weeks

(2015) Romina Quercia et al.   CLINICAL DRUG INVESTIGATION

Dolutegravir: A Next-Generation Integrase Inhibitor for Treatment of HIV Infection

(2014) D. A. Osterholzer et al.   CLINICAL INFECTIOUS DISEASES

Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial

(2014) Anton Pozniak et al.   LANCET INFECTIOUS DISEASES

Obesity Trends and Body Mass Index Changes After Starting Antiretroviral Treatment: The Swiss HIV Cohort Study

(2014) Barbara Hasse et al.   Open Forum Infectious Diseases

Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection

(2013) Sharon L. Walmsley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-term Treatment With Raltegravir or Efavirenz Combined With Tenofovir/Emtricitabine for Treatment-Naive Human Immunodeficiency Virus-1–Infected Patients: 156-Week Results From STARTMRK

(2011) Jürgen K. Rockstroh et al.   CLINICAL INFECTIOUS DISEASES

Cardiovascular risk factors in patients on long-term treatment with nevirapine- or efavirenz-based regimens

(2011) P. Maggi et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial

(2011) Jan van Lunzen et al.   LANCET INFECTIOUS DISEASES